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Raman spectroscopyIn breast cancer the presence of cells undergoing the epithelial-to-mesenchymal transition is indicative of
metastasis progression. Since metabolic features of breast tumour cells are critical in cancer progression and
drug resistance, we hypothesized that the lipid content of malignant cells might be a useful indirect measure
of cancer progression. In this studyMultivariate Curve Resolutionwas applied to cellular Raman spectra to assess
the metabolic composition of breast cancer cells undergoing the epithelial to mesenchymal transition. Multivar-
iate Curve Resolution analysis led to the conclusion that this transition affects the lipid proﬁle of cells, increasing
tryptophan butmaintaining a low fatty acid content in comparisonwith highlymetastatic cells. Supporting those
results, a Partial Least Square-Discriminant analysis was performed to test the ability of Raman spectroscopy to
discriminate the initial steps of epithelial to mesenchymal transition in breast cancer cells. We achieved a high
level of sensitivity and speciﬁcity, 94% and 100%, respectively. In conclusion, Raman microspectroscopy coupled
with Multivariate Curve Resolution enables deconvolution and tracking of the molecular content of cancer cells
during a biochemical process, being a powerful, rapid, reagent-free and non-invasive tool for identifying
metabolic features of breast cancer cell aggressiveness at ﬁrst stages of malignancy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Genetically altered neoplastic cells have special metabolic require-
ments [1]. Recent molecular studies of cancer revealed that oncogenes
directly affect cellular energy metabolism [2].
An early and universal feature of tumours is the activation of lipid
metabolism secondary to the activation of the lipogenic enzymes in
the malignant process [3]. Increased lipogenesis is a hallmark of many
cancers including breast carcinomas [4]. Lipid metabolism related
genes in breast cancer cells have been studied describing a lipogenic
phenotype [3]. Gene silencing experiments with seven genes (ACACA,
ELOVL1, FASN, INSIG1, SCAP, SCAP, SCD, THRSP) indicated that reduc-
tion of the lipidomic proﬁles disrupted the viability of breast cancer
cells [5].
In addition, the constitutive activation of signalling cascades that
stimulate cell growth has a profound impact on anabolic metabolism
[6]. One of the principal mechanisms of aerobic glycolysis resides inomèdiques August Pi i Sunyer-
Oncology, Centre de Recerca
Barcelona, Spain. Tel.: +34 93
aps.org/ (A. Sierra).the activation of hypoxia-inducible factor (HIF), a transcription factor
activated by hypoxic, oncogenic, metabolic and oxidative stress, and
also involved in epithelial-to-mesenchymal transition (EMT), the initial
signal of the lethal metastatic phenotype of breast cancer cells [7]. In-
deed, the preferential expression of EMT-related genes has been found
in basal-like breast tumours, the most invasive breast carcinomas [8]
with the worst prognosis and greatest resistance to chemotherapy [9].
Basal-like tumour cells express markers characteristic of the normal
mammary gland myoepithelium, such as epidermal growth factor
receptor (EGFR), p63 and basal cytokeratins CK14, CK5/6 and CK17
[10]. Cellular remodelling occurring as a consequence of EMT, whereby
cells have altered responses to agents in the circulatory system or sec-
ondary tumour site, could be advantageous for the process ofmetastasis
[11,12]. EMT confersmesenchymal properties on epithelial cells and has
been closely associatedwith the acquisition of aggressive traits by carci-
noma cells [13]. Moreover, the dynamic interactions among epithelial,
self-renewal and mesenchymal gene programmes determine the plas-
ticity of epithelial tumour-initiating cells [14].
A close relationship between changes in fatty acid metabolism
is associated to cell motility and the proclivity to breast cancer cells un-
dergoing EMT [15]. We have previously characterized the metabolic
phenotype of breast cancer cells by using Raman microspectroscopy
(RS) combined with Principal Component Analysis (PCA), based on a
panel of small molecules derived from the global or targeted analysis
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a useful technique for stratifying breast cell malignancy, being well
correlated with the EMT phenotype and the expression of SREBP-1c
and ABCA1 genes [16]. Since, metabolic features of breast tumour cells
are critical in cancer progression and drug resistance [9,17], there exists
a need to develop alternative/adjunct, user-freed, cost effective, rapid,
objective and unambiguous methods for the early detection and diag-
nosis of metastatic breast cancer cells.
Recently, some unmixing algorithms have been used to decompose
the Raman spectra into different molecular components in areas such
as Raman imaging: Vertex Component Analysis (VCA) [18–20] and
Multivariate Curve Resolution (MCR) [21]. In the last decade, MCR
algorithm has been applied in a broad range of chemical analysis
[22–24] and recently to Raman images [25,26]. Multivariate Curve
Resolution-Alternating Least Squares (MCR-ALS) stands out because of
its ﬂexibility to include initial estimates and constrains in the iterative
resolution procedure [21]. The output of the MCR-ALS analysis gives
more chemically and physically understandable results than classical
techniques such as PCA, where only a mathematical exploration of the
data can be performed [27–30]. Thus, being a powerful candidate tool
to deconvolve key molecular signatures from the Raman spectra and
monitor the biochemical composition of the sample over the process
studied [31]. In the present research we used MCR-ALS algorithm to
study cellular Raman spectra. The algorithm allowed the deconvolution
of meaningful molecular Raman spectra of biomolecules (metabolites)
that change its concentration in the cells under study. Furthermore,
and supporting MCR results, a Partial Least Square-Discriminant analy-
sis (PLS-DA) was performed to test the ability of discrimination with RS
of the EMT from initiating breast cells, achieving a high level of sensitiv-
ity and speciﬁcity. Overall the results presented in this paper report the
ﬁrst application of MCR to RS to deconvolve and track the molecular
content of initiating breast cancer cells during the EMTprocess, suggest-
ing that RS combined with MCR and PLS-DA is a powerful diagnostic
tool for identifying metabolic features of the ﬁrst stages of malignancy
and breast cancer cell aggressiveness.2. Material and methods
2.1. Cell cultures
MCF10A cells were obtained from theAmerican Type Culture Collec-
tion and were grown in DMEM/F12 medium supplemented with 5%
horse serum, 1 mM pyruvate, 2 mM L-glutamine, 0.01 mg/ml bovine
insulin, 20 ng/ml EGF, 1 mg/ml hydrocortisone and 100 ng/ml tetanus
toxin in 5% CO2–95% air at 37 °C in a humidiﬁed incubator.
MDA-MB-435 cells maintained under standard conditions in a 1:1
(v/v) mixture of DMEM and Ham F12 medium (DMEM/F12) supple-
mented with 10% foetal bovine serum (FBS), 1 mM pyruvate and
2 mM L-glutamine, in the same incubator conditions as described
above were used in some experiments [32].Fig. 1. Raw Raman spectra from MCF10 conﬂuent and MCF10 sparse cells and MDA-MB-
435 metastatic cells. The spectra shown have been the background subtracted similarly
as in [15] and a Multiple Scatter Correction was performed.2.2. Sample preparation
Eachmeasurement required 3 × 105 cells, or 3 × 104 cells forMCF10A
cells in conﬂuent or sparse conditions. Cells were seeded in six-well
plates (Becton Dickinson, NJ) over a quartz crystal (ESCO products, Oak
Ridge, NJ), which was used to reduce the background signal. After 24 h,
the cells were ﬁxed with 4% cold paraformaldehyde (PFA) in PBS 1× for
15 min, washed 3 times for 10 min with PBS 1× (until no PFA residues
were present) and maintained in the same PBS 1× solution at 4 °C
until measurements. The complete washing of the cells also
ensures that no residues of different culture media or other
chemicals are present and therefore the cells are measured under
the same conditions.2.3. Raman spectroscopy
The Renishaw Raman system (Apply Innovation, Gloucestershire,
UK) comprises a 514 nm laser that supplies an excitation beam of
about 5 mWpower, which is focused onto the sample via a microscope
using an air 60× objective (Leica, 0.75 NA). The same objective collects
the scattered light from the sample and directs it to the spectrometer.
The spectrometer processes this scattered light, by rejecting the
unwanted portion and separating the remainder into its constituent
wavelengths. The Raman spectrum is recorded on a deep depletion
charge-coupled device (CCD) detector (RenishawRenCam). The record-
ed Raman spectrum is digitalized and displayed on a personal computer
using RenishawWiRE software, which allows the experimental param-
eters to be set. For experiments, one spectrum was collected per cell in
the cytoplasm, near the nucleus but outside the endothelial reticulum
[15], focusing light at 3 μ inside the quartz window.Wewere interested
in obtaining the most number of cells measured rather than study the
intracellular domain. That is why we acquired one Raman spectra per
cell, obtaining a total of 20 spectra per cell line studied: MCF10 conﬂu-
ent, MCF10 sparse and MDA-MB-435. To ensure that changes in the
spectra among different cell lines were due to its intrinsic biochemical
content and not due to changes in other factors that could be out of con-
trol (setup alignment, background signals, temperature, conditions in
sample preparation …), we measure all cell lines in the same day
under exactly the same conditions. Replications of the experiment
were performed in other different days andwere comparable, providing
similar results. The quartz in which the cells were grown and ﬁxed
was translated to a magnetic ﬂuid chamber (Live Cell Instruments),
ﬁlled with PBS and closed with other quartz coverslip. For Raman
measurements the quartz containing the cells was placed on the top
(with cells inside the ﬂuid chamber) to be measured with the upright
microscope.
Before including Raman spectra in the multivariate statistical
techniques, correct pre-processing must be performed. Spectra shown
in Fig. 1 have been pre-processed using the following methods:
subtracting ﬂuorescence background [15], comic spike removal, smooth-
ing (5 points averaging) and multiple scattering correction (MSC); MSC
algorithm was used to correct for differences in global intensity among
the spectra. We used a custom-made Labview and Matlab code to
perform all these preprocessing methods. However because there is
still the presence of background signals from quartz or PBS, with the
use of MCR-ALS algorithm we subtracted those signals at the same
time that we looked for molecular components (explained in the next
section on Statistical analysis). For Raman spectral analysis, the region
between 1015 and 1110 cm−1 was removed because it contained a
background-related signal that reduced the quality and interpretability
of our statistical models.
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Two multivariate techniques were performed on cellular Raman
spectra, in order to evaluate the spectral differences among the
cancerous cell lines studied and to develop a model allowing their
discrimination and classiﬁcation: MCR and PLS-DA.
In Multivariate Curve Resolution (MCR) [21], a bilinear relation of
the spectrum is assumed from the matrix, taking into account that the
total Raman spectra contained in X matrix can be modelled as the con-
tribution of pure molecular spectra (S) multiplied by the concentration
of each pure molecular component (C), X = CST + E, where X is
the Raman spectra acquired matrix, C is the concentration matrix
transposed and E is the matrix of spectral errors.
The algorithm used was Multivariate Curve Resolution-Alternating
Least Squares (MCR-ALS). Using a ﬁrst PCA on the dataset of spectra,
the number of components necessary to explain the variance in
the data was selected, accounting for 95% of the total variance. For
ALS optimization, constraints of non-negativity in the spectra and con-
centrations were applied. A limit of 300 iterations was applied to
reach the 0.95 conﬁdence limits. MCR-ALS allowed visualization of the
bands (biomolecular vibrations) responsible for the changes inmetabo-
lite concentrations in the different cell lines. Finally, ﬁve molecular
components were deconvolved from the spectra.
In order to deconvolve from the spectra the possible contributions of
the background signals we include in the Raman spectra matrix X, 5
spectra obtained from the PBS solution at the same focal distance
where the cells were measured (3 μm). In this way, the algorithm ex-
tracts one component that contains the spectral proﬁles of background
signals from the quartzwindow and PBS solution. These ﬁve spectra are
represented by stars in the plots and they always contain very low levels
of other cellular components as expected. A remaining contribution from
quartz signal was arising at 1100 cm−1 in other components, and for this
reason we exclude from the analysis this region to ensure that the
components deconvolved were not mixed with background signals.
PLS-DA [15] is a supervised classiﬁcation method in which knowl-
edge of the sample is included (in our case metastatic, malignant and
benign MCF10A phenotypes). PLS-DA employs the fundamental princi-
ple of PCA but further rotates the component (latent variables, LVs) by
maximizing the covariance between the spectral variation and group
afﬁnity so that the LVs explain the diagnostically relevant variations
rather than the most prominent variations in the spectral dataset.
The performance of the PLS-DA diagnostic algorithm was validated
using leave-one-out cross validation methodology. The number of
retained LVs was determined based on the minimal root mean square
error of cross validation (RMSECV) curves.
Multivariate statistical analysis was performedusing the PLS toolbox
(Eigenvector Research,Wenatchee,WA) in theMatlab (Mathworks Inc.,
Natick, MA) programming environment. Before including Raman
spectra in the multivariate statistical techniques, correct preprocessing
must be performed (see Raman spectroscopy section).
2.5. Gene expression analysis
Transcriptomic data fromMCF10A cells cultured in sparse or conﬂu-
ent conditions with accession number GSE8430 [12] were downloaded
from theGene ExpressionOmnibus database [33]. In addition, a series of
matrix including normalized data from GSE18070 that contains differ-
ent strands of k-ras transfected MCF10A cells was downloaded from
the GEO repository [33]. The median z-score between the six replicates
included in the experimentwas calculated for each probe and then used
to rank all genes by their level of expression. To assess gene expression
differences, a t-test between all probe sets from three hybridized MIII
samples (cells with ability tometastasize in vivo) and threeMII samples
(cellswithoutmetastasis ability) was conducted. Then the 33,853 genes
included in the array (Affymetrix U133 Plus 2.0) were ranked based on
their statistic expression level.A pre-ranked GSEA (Gene Set Enrichment Analysis) using both lists
of ranked genes was run. Only 81 gene sets were related to “fatty acid”,
“lipid”, “glucose”, “cholesterol”, “EMT” and “tryptophan”; and those
gene sets were described by Charafe et al. [34] including differentially
expressed genes between different kinds of breast cancer that were in-
cluded in the analysis. The statistical signiﬁcance of the enrichment
scorewas calculated by permuting the genes 1000 times as implemented
in the GSEA software. Functional terms were considered to be signiﬁcant
at FDR q-value of 25%.
The conventional statisticalmethods formicroarray gene expression
analysis choose a list of differentially expressed genes based on a
p-value corrected by multi-testing. Using this astringent criterion, a
large number of genes that do in fact contribute to the studied pheno-
type could be missed. The GSEA (gene set enrichment analysis)
approach was designed to address the limitation of single gene analysis
since it uses all transcriptomic information included in the array [35].
All computations were performed using R statistical software and
Bioconductor [36].3. Results
3.1. Multivariate Curve Resolution (MCR) algorithm provides an accurate
evaluation of Raman spectroscopy (RS)
We use MCR to efﬁciently disentangle pure molecular information
encoded in complex spectrum such as Raman.
To distinguish the metabolic features of cells with the EMT pheno-
type [37,38], we used MCF10A cells, benign breast tumour cells, unable
to spread outside the basal membrane, despite their basal-like pheno-
type. It has been described that MCF10A sparse cultures presented
many features of mesenchymal cancer when compared with MCF10A
conﬂuent [12]. The more aggressive MDA-MB-435 cell line showed
an even more noticeable mesenchymal phenotype characterized by
a high level of expression of vimentin and N-cadherin [39,40] and
a down-regulation of E-cadherin [40]. Therefore we used MCF10A
conﬂuent and sparse culture conditions as a signal of the initiation of
metastasis progression, to characterize the spectroscopic parameters
of a prototype of metastasis-initiating cells in comparison with the
highlymetastatic MDA-MB-435 breast cancer cells, a widely recognized
metastatic cells in which the degree of metastaticity has been related to
the polyunsaturated fatty acid contents by Raman analysis [41].
Since we have previously distinguished conﬂuent and sparse
MCF10A, according to the total unsaturated fatty acids (TUFA) band in-
tensity (in the C\H stretching region of the spectra (2800–3100 cm−1),
[15], RS of both phenotypes (conﬂuent and sparse MCF10A) was
acquired in the ﬁngerprint region (600–1800 cm−1). Fig. 1 shows the
row spectrum of the three different phenotypic cells analysed (MCF10
sparse, conﬂuent and MDA-MB-435) after background subtraction and
MSC correction. Band characteristic of the Raman spectra of molecules
is presented in Table 1. The MCR-ALS algorithm was then used to
deconvolve from these raw spectra the Raman spectra of the metabo-
lites that differed among the cell groups. One problem that could arise
in resolution analysis methods is that the components deconvolved
from the experimental Raman spectra are mixed with background sig-
nals and are therefore difﬁcult to interpret. This problem was solved
by adding to the data set a small number of spectra obtained from the
PBS (buffer, not cells) at the same focal distance at which the cellular
spectra were acquired. Including this extra information in the MCR-
ALS algorithm allows the deconvolution of a component that contains
only background spectra (quartz and water). Therefore, the remaining
components only account for the differences in the metabolite content
in the cells. Four pure spectra were deconvolved from inherent cellular
components and are shown in Fig. 2. Score plots relating to different
components are presented in Fig. 3. The control spectra from PBS were
plotted on the score plot as blue crosses and were always around the
Table 1
Band assignments for the Raman spectra corresponding to components 1, 2, 4 and 5 obtained byMCR analysis of sparse and conﬂuentMCF10A cells andMDA-MB-435 cells. Assignments
were based on Refs. [34–37]. PA: phenylalanine; FA: fatty acids; T: tryptophan; K: keratin; A: amide; PS: polysaccharides.
Component 1 Component 2 Component 4 Component 5
Band (cm−1) Assignment Band (cm−1) Assignment Band (cm−1) Assignment Band (cm−1) Assignment
1001 PA 1123 FA 940 PS 936 K
1170 PA 1260 FA 986 PS 1001 PA
1204 T 1300 FA 1125 PS 1235 AIII, K
1237 AIII 1438 FA 1187 PS 1240 AIII, K
1300 T 1207 PS 1296 K
1315 T 1337 PS 1335 K
1336 T 1365 PS 1448 K
1359 T 1452 PS 1650 K
1448 T, CH2 deformation
1479 T, AII
1587 T
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indicating the absence of those molecules from the spectra.
With the help of previously published Raman databases [42–45]
and measuring the Raman spectra of pure molecules, we identiﬁed
component 1 as tryptophan, component 2 as fatty acids and component
5 as cytokeratin. Component 4 did not have a priori clear assignment,
whereas component 3 accounted only for background contribution
(Fig. 2). Table 1 lists the assigned metabolites in each component
[43,44]. Component 1 included mainly phenylalanine and trypto-
phan. Two bands, at 1001 cm−1 and 1170 cm−1, correspond to
phenylalanine, and six to tryptophan: 1204, 1300, 1315, 1336, 1359
and 1587 cm−1.Fig. 2. Component spectra obtained by Raman microspectroscopy deconvolved from MCR
characteristic bands of components 1, 2, 4 and 5 are indicated in each spectrum. AssignmentsComponent 2 included bands assigned to fatty acids: 1123, 1260,
1300 and 1438 cm−1. All the bands contained in component 5 were
identiﬁed as keratin (936, 1296, 1335, 1448 and 1650 cm−1) and
amide III (1235 and 1240 cm−1). Therefore, MCR resolved meaningful
components in the spectra with respect to classical techniques such as
Principal Component Analysis (PCA), demonstrating a high capacity to
deconvolve the pure cell component spectra of molecules from a set of
Raman spectra. Moreover, the outputs of the statistical analysis provid-
edmore chemically and physically understandable results than classical
techniques such as PCA, via which only a mathematical exploration of
the data can be performed and components have mixed molecular
contributions and negative loadings.analysis using sparse and conﬂuent MCF10A cells and MDA-MB-435 cells. The main
were based on Refs. [34–36].
Fig. 3.MCR score plot for components represented in Fig. 2. ConﬂuentMCF10A cells (green asterisks), sparseMCF10A cells (red triangles) andMDA-MB-435 cells (dark blue squares). Light
blue crosses are control spectra obtained from the PBS solution at the same focal depth. The arrows indicate an increase in the epithelial-to-mesenchymal transition (EMT), the lipid
phenotype (LP), the tryptophan (T) content or the polysaccharide (PS) content. a) Component 5 (keratin), a marker of EMT, is plotted with component 2, which was assigned to fatty
acids, an indicator of the LP. b) Component 1, assigned to tryptophan, is plotted with component 2 (fatty acids). c) Keratin is plotted with component 1, assigned to tryptophan.
MCF10A cells in both culture conditions are completely separated by differences in the levels of both components. d) Component 4, assigned hypothetically to polysaccharides, is plotted
with component 2 (fatty acids). MDA-MB-435 cells are clearly split into two subpopulations: SP435A (with higher lipid content) and SP435B (with lower lipid content).
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We conducted an in-depth analysis of the most signiﬁcant differ-
ences between conﬂuent and sparse MCF10A cells to assess the differ-
ent proﬁles of the spectral composition and to build a classiﬁcation
algorithm for the discrimination of EMT cells with the metastatic-
initiating phenotype from the highly metastatic MDA-MB-435 cells.
We plotted the contributions of component 2 (fatty acids) with
respect to component 5 (keratin) (Fig. 3a). EMT appeared inversely cor-
related with keratin, with MDA-MB-435 cells having low keratin level
whereas conﬂuentMCF10A cells had the highest (Fig. 3a and c). Compo-
nent 2 (fatty acid) separated two MDA-MB-435 cell populations:
SP435A with the highest fatty acid content, and SP435B with a moder-
ate fatty acid increase. In contrast, sparse MCF10A cells had a low
keratin and increased fatty acid content compared with conﬂuent
MCF10A cells, more similar to SP435A. Indeed, the most lipid accumu-
lating cells were sparse MCF10A and SP435A. Thus, RS accurately classi-
ﬁed EMT based on a low keratin and a high lipid content, so-called lipid
phenotype (LP). In addition, component 1 identiﬁed as tryptophan (T)
clearly segregated sparse MCF10A from the rest of the cells, suggesting
that high levels of this metabolite were an idiosyncratic element of
the EMT phenotype (Fig. 3b and c). Taking into account scores ontryptophan and fatty acids (Fig. 3b), the aggressive metastatic pheno-
type of MDA-MB-435 cells was strongly associated with an increase in
phospholipids with low tryptophan content (Fig. 3b). On the other
hand, MDA-MB-435 cells were split into two clear groups, one with
low lipid content and the otherwith the highest lipid content, according
to its heterogeneity [46]. Moreover, in Fig. 3d, it was possible to distin-
guish the highest fatty acid SP435A cells (with a lipid phenotype)
from SP435B cells (with a low lipid concentration and increased levels
of component 4), suggesting that this componentmay act as an alterna-
tive fuel source for MDA-MB-435 cells with a lower lipid content [46].
In addition, some bands in component 4 (see Table 1) can be assigned
to polysaccharides (PS). Therefore, component 4 could be related to
glucose metabolism. Furthermore, the cloud of sparse MCF10A cells
was displaced with respect to conﬂuent MCF10A cells in Fig. 2d. Sparse
MCF10A showed a high LP and low PS content whereas conﬂuent
MCF10A have higher PS and lower LP which supports PS as an alterna-
tive fuel source for low lipid accumulating cells.
To support MCR results and investigate the biomarker usefulness of
RS for diagnostic applications, we performed a PLS-DAmodel in order to
explore the ability of RS to differentiate between sparse and conﬂuent
MCF10A andMDA-MB-435 cells. Themodel (Fig. 4) gave 100% sensitiv-
ity and 100% speciﬁcity for discrimination of sparse MCF10A, 94%
Fig. 4.Results of PLS-DA analysis to explore the ability of RS to differentiate between sparse and conﬂuentMCF10A cells andMDA-MB-435 cells. Themodel gives 100% sensitivity and 100%
speciﬁcity for sparse MCF10A discrimination (a), 94% sensitivity and 89% speciﬁcity for conﬂuent MCF10A discrimination (b), and 80% sensitivity and 100% speciﬁcity for MDA-MB-435
identiﬁcation (c) using the cross-validation method venetian blinds with 7 splits.
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and 100% speciﬁcity for MDA-MB-435 using the cross validation
method venetian blindswith 7 splits. Overall we presented a clear strat-
iﬁcation method to differentiate the characteristic fatty acid accumula-
tion, which enriched by the increased tryptophan concentration in
sparse MCF10A cells constituted an initial EMT progression phenotype.
3.3. Differential expression of EMT genes supports RS metabolic phenotype
We performed functional enrichment analyses to support the
spectral differences between conﬂuent and sparseMCF10A cells accord-
ing to transcriptomic analysis. We used public transcriptomic data
downloaded from Gene Expression Omnibus database GSE8430 [12]
to search for functional differences between sparse and conﬂuent
cells. This dataset contains a normalized log ratio (z-score) for the dif-
ferences in expression of 11,500 probe sets representing 9300 genes
from the CNIO Homo sapiens Oncochip 2. Genes were ranked by their
median z-score and gene set enrichment analysis (GSEA) algorithm [47]
was applied to identify speciﬁc functions in the list of pre-ranked genes.
A total of 71 gene sets including the keywords “fatty acid”, “lipid”,
“glucose”, “cholesterol”, “EMT” and “tryptophan”, and those gene sets
described by Charafe et al. [34], including genes that are differentially
expressed in different kinds of breast cancer, were tested (Table 2).
Genes that were downregulated in luminal-like breast cancer cell
lines in comparison with mesenchymal-like ones [34] were expressed
in sparseMCF10A (FDR b 0.000), whereas conﬂuentMCF10A contained
genes that were upregulated in luminal-like breast cancer cell lines
in comparison with the mesenchymal-like ones (FDR b 0.000). As
expected, sparse cells showed a signiﬁcant enrichment in genes that
were upregulated in EMT whereas conﬂuent cells were enriched
in EMT downregulated genes, pointing to a mesenchymal phenotype.
Surprisingly, both up- and downregulated EMT genes described
by Jechlinger et al. [48] were signiﬁcant gene sets in conﬂuent cells,
but downregulated genes were much more statistically signiﬁcant
(FDR = 0.008).
Fatty acid and glucose metabolic functions differentiated conﬂuent
and sparse MCF10A cells. The metabolic phenotype of sparse MCF10Acells was characterized by genes involved in glucose deprivation
(FDR = 0.0020) and glucose transport (FDR = 0.120), whereas in con-
ﬂuent MCF10A cells the proﬁling showed an enrichment in genes in-
volved in glucose metabolism (FDR = 0.032). Moreover, differences
included increased fatty acid metabolism (FDR = 0.240) and fatty acid
oxidation (FDR = 0.150) in conﬂuent MCF10A. Since fatty acid metabo-
lism was increased in these cells their glucose dependence was mini-
mized with regard to sparse cells, suggesting that conﬂuent and sparse
MCF10A cells have a different metabolic phenotype in both conditions.
One of the ﬁrst metabolic alterations observed in cancer cells was
the higher dependence upon glucose for their growth, the so-called
Warburg effect, indicating that the EMT process in sparse MCF10A
cells altered their metabolism, giving them more oncogenic proper-
ties [49]. Moreover, tryptophanmetabolism and tryptophan catabolism
were statistically signiﬁcant functions (FDR = 0.190 and 0.136 respec-
tively) in conﬂuent cells, which expressed lower levels of tryptophan
than sparse cells.
Due to the low number of metabolism-related genes represented in
the GEO2603 chip that hybridized with sparse and conﬂuent MCF10A
cells (Supplementary Table 1), an alternative analysis using data from
Papageorgis et al. [50] was conducted. To assess differences in gene
expression, a t-test between all probe sets from three hybridized MII
samples (k-ras transfected MCF10A cells without metastasis ability)
andMIII samples (k-ras transfectedMCF10A cells with ability tometas-
tasize in vivo) was conducted at the transcriptomic level. The 33,853
genes included in the array (Affymetrix U133 Plus 2.0) were ranked
by the t-statistic. In this way, positive values corresponded to a MIII
phenotype whereas negative values were characteristic of MII. A GSEA
using the same gene sets as those in the GSE8430 study was then run.
A total of 33,853 genes were hopefully hybridized on the chip, so
more metabolism-related genes were included in the functional
enrichment analysis. Signiﬁcantly enriched functions at FDR 25%
were found such as regulation of insulin secretion by free fatty acids
(FDR = 0.150) in MIII cells, whereas in MII cells (see Table 3) glucose
transporters (FDR = 0.189), lipid rafts (FRD = 0.029), phospholipid
binding (FDR = 0.124) and cholesterol biosynthesis (FDR = 0.002),
among others, were enhanced.
Table 2
Functional enrichment in sparse and conﬂuent MCF10 A cells.
GSEA gene set standard name Brief description Source Nominal p-value FDR q-value
Sparse
Cui glucose deprivation Representative genes up-regulated in MiaPaCa2 cells (pancreatic cancer) under glucose-deprived conditions. Pubmed: 17409444 0.002 0.002
Reactome glucose transport Genes involved in glucose transport REACTOME database 0.046 0.120
Sarrio epithelial mesenchymal transition up Genes up-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared
to those grown at high (epithelial, basal-like phenotype) conﬂuence.
Pubmed: 18281472 b0.000 b0.000
Gotzmann epithelial to mesenchymal
transition up
Genes up-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during
epithelial to mesenchymal transition (EMT).
Pubmed: 16607286 0.009 0.031
Charafe breast cancer luminal vs mesenchymal down Genes down-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones Pubmed: 16288205 b0.000 b0.000
Charafe breast cancer basal vs mesenchymal down Genes down-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones. Pubmed: 16288205 0.238 0.144
Conﬂuent
Glucose metabolic process Genes annotated by the GO term GO: 0006006. The chemical reactions and pathways involving glucose, the
aldohexose gluco-hexose.
D-glucose is dextrorotatory and is sometimes known as dextrose; it is an important source of energy for
living organisms and is found free as well as combined in homo- and hetero-oligosaccharides and polysaccharides.
GO database 0.012 0.032
KEGG fatty acid metabolism Fatty acid metabolism KEGG database 0.032 0.24
Reactome activated AMPK stimulates fatty acid
oxidation in muscle
Genes involved in activated AMPK stimulates fatty-acid oxidation in muscle REACTOME database 0.043 0.15
KEGG tryptophan metabolism Tryptophan metabolism KEGG database 0.100 0.190
Reactome tryptophan catabolism Genes involved in tryptophan catabolism REACTOME database 0.146 0.136
Jechlinger epithelial to mesenchymal transition down Genes down-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 in the EpH4 cells
(mammary epithelium cell line transformed by HRAS.
Pubmed: 14562044 0.002 0.008
Gotzmann epithelial to mesenchymal transition down Genes down-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial
to mesenchymal transition (EMT).
Pubmed: 16607286 b0.000 0.016
Sarrio epithelial mesenchymal transition down Genes down-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared
to those grown at high (epithelial, basal-like phenotype) conﬂuence.
Pubmed: 18281472 0.002 0.015
Jechlinger epithelial to mesenchymal transition up Genes up-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 in the EpH4 cells
(mammary epithelium cell line transformed by HRAS.
Pubmed: 14562044 0.030 0.067
Charafe breast cancer basal vs mesenchymal up Genes up-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones. Pubmed: 16288205 b0.000 b0.000
Charafe breast cancer luminal vs mesenchymal up Genes up-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones. Pubmed: 16288205 b0.000 b0.000
Charafe breast cancer luminal vs basal down Genes down-regulated in luminal-like breast cancer cell lines compared to the basal-like ones. Pubmed: 16288205 b0.000 b0.000
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Table 3
Functional enrichment in MIII and MII cells.
GSEA gene set standard name Brief description Source Nominal p-value FDR q-value
MIII
Reactome regulation of insulin secretion by free fatty acids Genes involved in regulation of insulin secretion by free fatty acids REACTOME database 0.050 0.150
Jechlinger epithelial to mesenchymal transition up Genes up-regulated during epithelial to mesenchymal transition (EMT) induced
by TGFB1 in the EpH4 cells (mammary epithelium cell line transformed by HRAS).
Pubmed: 14562044 b0.000 b0.000
Anastassiou cancer mesenchymal transition signature Genes in the ‘mesenchymal transition signature’ common to all invasive cancer types. Pubmed: 22208948 b0.000 b0.000
Gotzmann epithelial to mesenchymal transition up Genes up-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic
phenotype) during epithelial to mesenchymal transition (EMT).
Pubmed: 16607286 b0.000 b0.000
Sarrio epithelial mesenchymal transition up Genes up-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype)
compared to those grown at high (epithelial, basal-like phenotype) conﬂuency.
Pubmed: 18281472 0.004 0.013
Charafe breast cancer luminal vs mesenchymal down Genes down-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones Pubmed: 16288205 b0.000 b0.000
Charafe breast cancer basal vs mesenchymal down Genes down-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones. Pubmed: 16288205 b0.000 b0.000
Charafe breast cancer luminal vs basal down Genes down-regulated in luminal-like breast cancer cell lines as compared to the basal-like ones. Pubmed: 16288205 b0.000 0.005
MII
Reactome glucose and other sugar SLC transporters Genes involved in glucose and other sugar SLC transporters Database: REACTOME 0.027 0.189
Lipid raft Genes annotated by the GO term GO: 0045121. Specialized membrane domains composed mainly
of cholesterol and sphingolipids, and relatively poor in polyunsaturated lipids such as glycerophospholipids.
The formation of these membrane domains is promoted by the presence of cholesterol in the lipid bilayer:
the rigid hexagonal rings of cholesterol can pack tightly against the saturated hydrocarbon chains of some
membrane lipids, allowing these lipids to assemble into cohesive units ﬂoating in the mass of loosely packed
polyunsaturated plasma membrane components.
Database: GO b0.000 0.029
Lipid homeostasis Genes annotated by the GO term GO: 0055088. Any of the processes involved in the maintenance of an
internal equilibrium of lipid within an organism or cell.
Database: GO 0.010 0.066
Lipid transporter activity Genes annotated by the GO term GO: 0005319. Enables the directed movement of lipids into, out of, within
or between cells.
Database: GO 0.012 0.115
Phospholipid binding Genes annotated by the GO term GO: 0005543. Interacting selectively with phospholipids, a class of lipids
containing phosphoric acid as a mono- or diester.
Database: GO 0.010 0.124
Reactome cholesterol biosynthesis Genes involved in cholesterol biosynthesis Database: REACTOME b0.000 0.002
Reactome transformation of lanosterol to cholesterol Genes involved in transformation of lanosterol to cholesterol Database: REACTOME 0.008 0.018
Reactome synthesis of bile acids and bile salts via
24-hydroxycholesterol
Genes involved in synthesis of bile acids and bile salts via 24-hydroxycholesterol Database: REACTOME 0.033 0.050
Goering blood HDL cholesterol QTL trans Top scoring trans-regulated expression quantitative trait loci (eQTL) inﬂuencing blood levels of high-density
lipoprotein (HDL) cholesterol.
Pubmed: 17873875 0.075 0.074
Reactome synthesis of bile acids and bile salts via 7-alpha-
hydroxycholesterol
Genes involved in synthesis of bile acids and bile salts via 7-alpha-hydroxycholesterol Database: REACTOME 0.080 0.086
Gotzmann epithelial to mesenchymal transition down Genes down-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during
epithelial to mesenchymal transition (EMT).
Pubmed: 16607286 0.017 0.173
Jechlinger epithelial to mesenchymal transition down Genes down-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 in the EpH4 cells
(mammary epithelium cell line transformed by HRAS).
Pubmed: 14562044 0.058 0.112
Charafe breast cancer luminal vs mesenchymal up Genes up-regulated in luminal-like breast cancer cell lines as compared to the mesenchymal-like ones. Pubmed: 16288205 b0.000 b0.000
Charafe breast cancer basal vs mesenchymal up Genes up-regulated in basal-like breast cancer cell lines compared to the mesenchymal-like ones. Pubmed: 16288205 b0.000 b0.000
Charafe breast cancer luminal vs basal up Genes up-regulated in luminal-like breast cancer cell lines compared to the basal-like ones. Pubmed: 16288205 0.072 0.198
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lial mesenchymal transition up” were signiﬁcantly associated with
the MIII phenotype, suggesting a parallel between the MIII vs. MII
comparison and the sparse MCF10A vs. conﬂuent MCF10A comparison
(FDR = 0.013). Along with this gene set, other sets including genes
upregulated in EMTwere found to be associated withMIII cells, where-
as datasets including downregulated genes in EMT were associated
with MII cells. As expected, MIII cells showed a more mesenchymal
phenotype, with signiﬁcant gene sets being those genes described by
Charafe et al. [34] as downregulated in basal and luminal breast cancer
sub-types.
According to these transcriptomic public data, we inferred that fatty
acid and glucose metabolic functions differentiate conﬂuent and sparse
MCF10A cells, then supporting the RS proﬁle.4. Discussion
To our knowledge this study is the ﬁrst time MCR has been used to
deconvolve and track the molecular content of cancer cells during the
EMT process, which involves biochemical changes linked with the
early metastatic phenotype of cancer cells. We have demonstrated
that the unsupervised computational MCR analysis resolves chemically
and physically meaningful component spectra from a set of mixed
Raman spectra, allowing the assignment of pure molecular spectra to
each component deconvolved and its contribution (concentration).
MCR is more powerful than the classical PCA technique, in which
the spectral signature in principal components can contain negative
regions, impeding the assignment of puremolecular spectra [30]. There-
fore, MCR is a good candidate for tracking the biochemical composition
of a biomedical sample during a transition involvingmolecular changes
such as in the early diagnosis of breast cancer. These resultswhich are in
tune with ﬁndings of earlier studies carried out with transcriptomics
andmolecular biological techniques, using normal and cancer cells, fur-
ther demonstrate the power of RS approaches in diagnostic applications
and in the knowledge of molecular processes of cancer cells.
During the last two decadesMCRhas been applied to awide range of
chemical data [22–24] and has been adapted to Raman spectral data
from biological tissues for imaging their molecular content [25,38].
High-contrast images of uterine tissue derived using Raman spectra
with an empty modelling approach of Multivariate Curve Resolution-
Alternating Least Squares [42] have been obtained. We have shown
the ability of MCR to track the biochemical composition of a biological
sample during a process involving molecular changes. These molecular
changes are sometimes masked by background signals in the Raman
spectra of cells. This is because cells need to be grown on a substrate
(normally glass) that contains Raman and ﬂuorescence bands, and
when acquiring the cellular spectra, the focal point needs to be very
close to the window, which in some cases covers part of the confocal
volume. The ability of MCR to deconvolve pure component spectra
and the ﬂexibility of MCR-ALS algorithm to include speciﬁc constrains
allow these undesired components to be removed and only the inherent
changes occurring in cellular RS to be analysed. Our results demonstrate
an improvement in the molecular characterization of cells when using
RS coupled with MCR-ALS.
MCR performed on the RS of conﬂuent and sparse MCF10A cells
identiﬁed the metabolic proﬁle of EMT, which is characterized by a de-
crease in the cytokeratin content and an increase in the fatty acid and
tryptophan content. These results are consistent with the gene proﬁle
attributed to altered lipid metabolism functions like fatty acid metabo-
lism and fatty acid oxidation, which increase in malignant cells [51].
Moreover, the PLS-DA analysis of the cellular Raman spectra classiﬁed
EMT cells in the ﬁngerprint region with 100% sensitivity and 100%
speciﬁcity (see Fig. 4), indicating that Raman spectra provide powerful
information allowing stratiﬁcation of cells by their metastasis initiation
process phenotype.MCF10A cells in conﬂuent conditions had the highest content of
cytokeratin according to the composition of their pre-EMT cytoskeleton.
In contrast, MCF10A cells that undergo EMT and MDA-MB-435 cells
contain abundant vimentin cytoskeleton [15]. Overall, there was a
clear difference between conﬂuent and sparse MCF10A cells, reﬂecting
the increased EMT of the latter. These cells can thus be stratiﬁed using
the lipid-accumulating phenotype proﬁle, which has been found in
themost aggressive cancer cells and is related to their increasedmigra-
tion in vitro [52]. Studies comparing the Raman spectrum of human
breast cancerous and non-cancerous tissues also showed that fatty
acid content and lipid proﬁle were signiﬁcantly different [53,54].
Moreover, the increased tryptophan concentration in sparse
MCF10A compared to conﬂuent and MDA-MB-435 cells might be
secondary to the catabolic activation of L-tryptophan by indoleamine
2,3-dioxygenase (IDO1). The consumption of this amino acid by cancer
cells has been related to immune system evasion [55]. Furthermore, the
role of IDO1 in tumour cells has been associated with cell cycle regula-
tory genes, increased proliferation and inhibition of apoptosis [56].
IDO inhibition with siRNA leads to diminished breast cancer cell prolif-
eration [57]. The activation of genes associated with the tryptophan
metabolism has been reported in other types of carcinoma such as the
cervical carcinoma, indicating a common metabolic change linked to
malignancy [58,59]. Tryptophanmetabolism could exert immunological
and non-immunological effects, in turn improving cancer progression.
Further studies in breast cancer cells are needed to understand the
speciﬁc role of this metabolite in the EMT process.
The EMT is one of the main mechanisms involved in breast cancer
metastasis and most likely contributes to metastasis in all types of car-
cinoma [49,60,61]. Data obtained by the evaluation of RS using MCR
were sensitive enough to detect differences in the breast cancer basal
phenotype, since all analysed cells have a basal phenotype and share
some similarities. The MDA-MB-435 cell population is basically fed by
components 2 (fatty acid) and 4 (polysaccharides). Indeed, MDA-MB-
435 cells can be split into two clear groups, onewith a low lipid content
(fatty acid) and higher levels of polysaccharides and the other with a
higher lipid content, indicating the important role of lipids as a fuel
source for metastatic cells under nutritional deprivation, which in turn
could inﬂuence metastasis organ-speciﬁcity [46,62].
Cancer is a very heterogeneous disease with a large number of
genetic alterations. The molecular characterization of cancer cells
provides interesting insights into breast cancer taxonomy but its imple-
mentation in clinical diagnosis is difﬁcult because it is very expensive
[63]. RS together with multivariate analysis has shown a high ability
to differentiate cells with different degrees of malignancy according to
their biochemical composition. This was validated by gene expression
analyses, which conﬁrmed that these differences in cell composition
were closely associated with alterations in lipid metabolism that are
associated withmalignancy. Compared with other decomposition tech-
niques used in RS, such as Principal Component Analysis, MCR analysis
gives more chemically and physically understandable results.
There is increasing evidence of the association between phospho-
lipids and cancer. The analysis of MCF10A cells showed initial changes
in the lipid content of cells associated with their EMT phenotype. In
carcinoma cells EMT is related to higher aggressiveness and invasive
and metastatic potential [64]. Activation of lipid metabolism is an
early event in carcinogenesis and also a hallmark of many cancers [5].
In our attempt to study the metabolic changes involved in the EMT
process we analysed sparse MCF10A cells, which show many features
of post-EMT cells in in vitro cell culture, such as increased motility
[12]. Our results clearly indicate that an increase in phospholipids is
associated with the EMT process in breast cells. Characterization of
this initial malignant process, which is closely related to metastasis
progression, might be useful for diagnostic purposes. The essential hall-
marks of cancer are intertwined with altered cancer cell-intrinsic
metabolism, either as a consequence or as a cause [2]. New approaches
based on a panel of small molecules derived from the analysis of
1794 M. Marro et al. / Biochimica et Biophysica Acta 1843 (2014) 1785–1795metabolic proﬁles of cells are being developed to characterize cancer
cell-speciﬁc metabolism [65]. Many observations during the early
period of cancer biology research identiﬁed metabolic alterations such
as the Warburg effect [49]. In this scenario RS supported by MCR can
provide a useful toolwithwhich to assess the biomolecular composition
of tumour cells and metastasis-initiating cells. The applications of spec-
troscopic methods in cancer detection open new possibilities in the
early stage diagnosis of breast cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.04.012.
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